The present invention concerns compounds inter alia according to general formula 1
a
. Compounds according to the invention are vasopressin V
1a
receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V
1a
receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
The present invention relates to compounds with vasopressin V1a antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin V1a antagonists for the treatment of certain physiological disorders, such as Raynaud's disease and dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea).